Your session is about to expire
← Back to Search
LY3537982 for Cancer
Study Summary
This trial is testing a new drug to see if it's safe and effective in cancer patients with a specific genetic mutation. Patients who have already tried the standard of care and couldn't tolerate it are eligible. The trial will last up to 2 years.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live vaccine in the last 30 days.I have an autoimmune disease treated with medication in the last 2 years.I have advanced NSCLC, haven't had treatment for it, and may start some treatments soon.My cancer has a KRAS G12C mutation.My organs are functioning well.I have stopped all cancer treatments and don't have major ongoing side effects.I have a serious heart condition.I am fully active or can carry out light work.My condition can be treated with the goal of curing it.I currently have an infection that is not being treated.I have not been diagnosed or treated for another cancer within the last 3 years.I can swallow pills.I have had treatment with oxaliplatin or irinotecan for advanced colorectal cancer.I had severe side effects from previous immunotherapy.My cancer is advanced, cannot be surgically removed, and/or has spread.I have brain metastases but am stable and haven't needed steroids in the last 2 weeks.I have previously been treated with a KRAS G12C inhibitor, except in specific allowed cases.
- Group 1: LY3537982 (Dose Escalation)
- Group 2: LY3537982 (Dose Expansion)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many locations have initiated this clinical trial?
"The current clinical trial seeks to enroll patients at various sites, such as South Texas Accelerated Research Therapeutics (START) in San Antonio, TX; Yale University School of Medicine in New Haven, CT; and NYU Langone in New york City. Additionally, there are 20 other medical centres participating."
Are there still opportunities for participants to join this research project?
"As per the information hosted on clinicaltrials.gov, this research endeavour is actively seeking out enrollees. The trial was initially shared on July 19th 2021 and has since been amended as of November 11th 2022."
Are there any limitations in terms of the number of enrollees for this clinical trial?
"Affirmative. The information found on clinicaltrials.gov confirms that this medical research project, which was launched in July of 2021, is currently enrolling volunteers. Approximately 360 patients need to be recruited from 23 different healthcare facilities."
Has the Food and Drug Administration granted its stamp of approval to LY3537982?
"As LY3537982 is only in its initial testing stage, our team at Power has assigned it a score of 1 due to the current scarcity of data indicating safety and efficacy."
What medical maladies is LY3537982 generally recommended to treat?
"LY3537982 is a common medical treatment for metastatic squamous cell carcinoma of the head and neck (hnscc) as well as malignant neoplasms, pancreatic cancer, and chemotherapy-induced disease progression."
What are the ultimate goals of this clinical experiment?
"The primary aim of this 21 day clinical trial is to analyse the safety and acceptability of LY3537982 when administered independently or in union with alternative investigational treatments. Secondary objectives comprise establishing early antitumor activity by measuring Disease Control Rate (DCR), Progression-free Survival (PFS) as well as evaluating Maximum Drug Concentration (Cmax)."
Is LY3537982 being trialed as part of any other clinical research projects?
"LY3537982 was first trialled at Mayo Clinic in Rochester back in the year 2002. This medicinal agent has since been scrutinized through 992 clinical studies, with 389 of these surveys currently enrolling patients - a large portion being undertaken out of San Antonio, Texas."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger